Akanda Past Earnings Performance
Past criteria checks 0/6
Akanda's earnings have been declining at an average annual rate of -53.9%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 6.2% per year.
Key information
-53.9%
Earnings growth rate
-20.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -6.2% |
| Return on equity | -696.7% |
| Net Margin | -1,269.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Akanda makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -32 | 5 | 0 |
| 31 Mar 24 | 2 | -32 | 6 | 0 |
| 31 Dec 23 | 2 | -32 | 6 | 0 |
| 30 Sep 23 | 3 | -24 | 10 | 0 |
| 30 Jun 23 | 3 | -12 | 13 | 0 |
| 31 Mar 23 | 3 | -10 | 17 | 0 |
| 31 Dec 22 | 3 | -8 | 20 | 0 |
| 30 Jun 22 | 0 | -7 | 15 | 0 |
| 31 Mar 22 | 0 | -7 | 10 | 0 |
| 31 Dec 21 | 0 | -2 | 3 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
Quality Earnings: Y230 is currently unprofitable.
Growing Profit Margin: Y230 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Y230 is unprofitable, and losses have increased over the past 5 years at a rate of 53.9% per year.
Accelerating Growth: Unable to compare Y230's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: Y230 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: Y230 has a negative Return on Equity (-696.7%), as it is currently unprofitable.